Implementation of the precision oncology program in catalonia's public health system: results, lessons learned, and future prospects
Por:
Mur, P, Pozuelo, A, Tabernero, J, Albanell, J, Bellosillo, B, Bosch, F, Briones, J, Brunet, J, Colomer, D, Domènech, M, Fontanet, JM, Matias-Guiu, X, Salazar, R, Vivanco-Hidalgo, RM, Mollà, M, Moreno, L, Prat, A, Ribera, JM, Clèries, R, Guarga, A, Espinàs, JA, Borras, JM
Publicada:
1 mar 2026
Ahead of Print:
1 sep 2025
Resumen:
PurposeThe Precision Oncology Program (POP) in Catalonia aims to provide equitable access to molecular testing for individuals with cancer, integrating Next-Generation Sequencing (NGS) into clinical practice to inform diagnosis, prognosis, and treatment decisions for both adult and pediatric patients with solid and hematologic malignancies, including somatic and germline alterations. This study evaluates the program's outcomes and impact.MethodsThis evaluation covers the period from the program's implementation in July 2021 through December 2023, with a more detailed analysis focusing on 2022-2023. The program involved 12 reference centers utilizing NGS technology for cancer genetic analysis, coordinated by CatSalut, the regional public health service payer. Data collected from each reference laboratory included the number of tests performed, types of tumor panels used, clinical indications, and associated outcomes.ResultsBetween July 2021 and December 2023, a total of 23,135 molecular tests were performed on 22,501 patients. The most frequently analyzed panels were for solid tumors (38.1%), hematologic cancers (17.3%), and germline mutations (42.2%). Pediatric patients accounted for 2.4% of the total. Notably, 24.7% of patients underwent a change in clinical management, contributing to more targeted treatment strategies, particularly in solid tumors (58.7%). Reports were delivered within an average of four weeks, meeting program benchmarks and facilitating timely decision-making. Sample submission compliance was high, reaching 98.5%.ConclusionsThis POP successfully addressed operational, financial, and logistic challenges, ensuring equitable access to molecular testing. This program led to more efficient and personalized clinical management, with growing impact on cancer care and patient outcomes.
Filiaciones:
Mur, P:
Catalonian Canc Strategy, Biomed Res Inst Bellvitge IDIBELL, Dept Hlth, Lhospitalet Llobregat Bar, Spain
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Pozuelo, A:
Catalonian Canc Strategy, Biomed Res Inst Bellvitge IDIBELL, Dept Hlth, Lhospitalet Llobregat Bar, Spain
Tabernero, J:
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Vall dHebron Hosp Campus, Dept Med Oncol, Barcelona, Spain
Vall dHebron Inst Oncol VHIO Barcelona, Barcelona, Spain
Albanell, J:
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Univ Pompeu Fabra, Hosp del Mar, Hosp del Mar Res Inst HMRIB, Dept Med Oncol,Canc Res Program, Barcelona, Spain
Bellosillo, B:
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Univ Pompeu Fabra, Hosp del Mar, Hosp Mar Res Inst HMRIB, Dept Pathol,Canc Res Program, Barcelona, Spain
Bosch, F:
Vall dHebron Inst Oncol VHIO, Lab Expt Hematol, Barcelona, Spain
Briones, J:
Hosp Santa Creu & Sant Pau, Dept Hematol, Barcelona, Spain
Brunet, J:
Girona Biomed Res Inst IDIBGI, Catalan Inst Oncol ICO, Hereditary Canc Program, Girona, Spain
Colomer, D:
Univ Barcelona, Hosp Clin Barcelona, Inst Invest Biomed August Pi & Sunyer IDIBAPS, Biomed Diagnost Ctr CBD,Hematopathol Sect,Dept Pat, Barcelona, Spain
Domènech, M:
Xarxa Assistencial Univ Manresa, Dept Med Oncol, Fundacio Althaia, Manresa, Spain
Fontanet, JM:
Catalan Hlth Serv CatSalut, Div Rat Use Med, Med Area, Barcelona, Spain
Matias-Guiu, X:
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Bellvitge Univ Hosp, Dept Pathol, Lhospitalet De Llobregat, Lleida, Spain
Arnau de Vilanova Univ Hosp, IDIBELL, Lleida, Spain
Salazar, R:
Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
Catalan Inst Oncol ICO, Dept Med Oncol, Oncobell Program IDIBELL, Barcelona, Spain
Univ Barcelona, Dept Clin Sci, Bellvitge Campus, Barcelona, Spain
Vivanco-Hidalgo, RM:
Agcy Hlth Qual & Assessment Catalonia AQuAS, Barcelona, Spain
Mollà, M:
Univ Barcelona, Hosp Clin Barcelona, Dept Radiat Oncol, Barcelona, Spain
Moreno, L:
Autonomous Univ Barcelona, Vall dHebron Univ Hosp, Vall dHebron Res Inst VHIR, Dept Pediat Oncol & Hematol, Barcelona, Spain
Prat, A:
Univ Barcelona, Clin Barcelona Comprehens Canc Ctr, IDIBAPS, Barcelona, Spain
Ribera, JM:
Autonomous Univ Barcelona, Germans Trias & Pujol Hosp, Catalan Inst Oncol ICO, Josep Carreras Leukemia Res Inst IJC, Badalona, Spain
Clèries, R:
Catalonian Canc Strategy, Biomed Res Inst Bellvitge IDIBELL, Dept Hlth, Lhospitalet Llobregat Bar, Spain
Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain
Guarga, A:
Catalonian Hlth Serv CatSalut, Hlth Serv Procurement & Assessment, Barcelona, Spain
Espinàs, JA:
Catalonian Canc Strategy, Biomed Res Inst Bellvitge IDIBELL, Dept Hlth, Lhospitalet Llobregat Bar, Spain
Borras, JM:
Catalonian Canc Strategy, Biomed Res Inst Bellvitge IDIBELL, Dept Hlth, Lhospitalet Llobregat Bar, Spain
Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain
Green Submitted, hybrid
|